Compare IKT & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IKT | EOLS |
|---|---|---|
| Founded | 2008 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.1M | 284.3M |
| IPO Year | 2020 | 2018 |
| Metric | IKT | EOLS |
|---|---|---|
| Price | $1.74 | $6.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $5.00 | ★ $15.50 |
| AVG Volume (30 Days) | 722.6K | ★ 886.6K |
| Earning Date | 03-26-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.76 | 1.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $297,176,000.00 |
| Revenue This Year | N/A | $13.27 |
| Revenue Next Year | N/A | $17.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.61 |
| 52 Week Low | $1.33 | $3.86 |
| 52 Week High | $2.26 | $10.62 |
| Indicator | IKT | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 59.44 |
| Support Level | $1.62 | $5.94 |
| Resistance Level | $1.74 | $6.40 |
| Average True Range (ATR) | 0.12 | 0.35 |
| MACD | -0.03 | -0.04 |
| Stochastic Oscillator | 30.84 | 62.36 |
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.